PAD A Call to Action. PAD: A Call to Action - What is peripheral arterial disease (PAD)? and why is it so dangerous? - Diagnosing PAD in the primary care.

Slides:



Advertisements
Similar presentations
Peripheral Arterial Disease Mehul Bhatt, MD Interventional Cardiology / Vascular Medicine Athens Heart Center.
Advertisements

Peripheral Artery Occlusive Disease
Peripheral Arterial Disease: missed opportunity for cardiovascular intervention Subhash Banerjee, MD Chief, Division of Cardiology VA North Texas Healthcare.
Peripheral Arterial Disease >Increasing Awareness >What is PAD >Risk factors >Symptoms of PAD >Screening & Treatment Options.
Advances in the Medical Management of Peripheral Arterial Disease Randall M. Zusman, MD Associate Professor of Medicine Harvard Medical School Director.
PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.
Newly diagnosed hypertensive patients with type 2 diabetes (n = 1544) Randomisation Avoid ACE inhibitors/ beta-blockers (n = 390) Tight BP control (n =
Copyright © 2009, Society for Vascular Surgery ®. All rights reserved. Your Vascular Health is a Matter of Life and Limb.
Ankle Brachial Index Measurement: What is it and why measure it? Mary O’Connor Cardiovascular Medical Science Liason Bristol Myers Squibb Guinness Storehouse.
Advances in the Medical Management of Peripheral Arterial Disease
Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
Epidemiology of Peripheral Vascular Disease Sohail Ahmed School of Population and Health Sciences.
CVD risk estimation and prevention: An overview of SIGN 97.
The Diagnosis and Treatment of Peripheral Vascular Disease
Presenter Disclosure Information Diane Bild, MD, MPH Screening for Subclinical Atherosclerosis as a Strategy for CVD Prevention FINANCIAL DISCLOSURE: None.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
IHS SDPI COMPETITIVE GRANT PROGRAM CVD RISK REDUCTION DEMONSTRATION PROJECT WHAT IS THE EVIDENCE? HOW ARE WE DOING? HOW CAN WE DO BETTER? Karl Hammermeister,
1 Women & Heart Disease Julia C. Orri, Ph.D. Biol. 330 November 21, 2006.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
Chapter 4 Cardiovascular disease
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Cardiovascular Disease in Women Module III: Risk Assessment Tool.
Screening for Abdominal Aortic Aneurysm Peter D. Newcomer, MD.
Metabolic Syndrome, Diabetes, and Cardiovascular Disease: Implications for Preventive Cardiology Nathan D. Wong, PhD, FACC, FAHA Professor and Director.
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
Peripheral Arterial Disease Education and ABI Training for Vascular Nurses Presented by The Society for Vascular Nursing Comprehensive In-Service Lecture.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
Advances in the Medical Management of Peripheral Arterial Disease Walter A. Tan, MD, MS Associate Professor of Medicine Clinical Associate Professor of.
STROKE STATS Third leading cause of death deaths a year strokes a year stroke survivors Leading cause of adult disability Source:
Peripheral Artery Disease (PAD) & Ankle Brachial Index (ABI) Marge Lovell RN CCRC CVN BEd MEd London Health Sciences Centre London, Ontario, Canada.
What Is Peripheral Vascular Disease? Daniel B. Walsh, M.D. Professor of Surgery, Section of Vascular Surgery Vice-Chair, Department of Sugery Dartmouth-Hitchcock.
PAD AND VASCULAR EVENTS  IC AS A DISEASE OFTEN REMAINS UN RECOGNISED. AS HIGH AS 75% OF PEOPLE WHO HAVE IC DO NOT SEEK MEDICAL HELP SINCE MANY PEOPLE.
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
Obesity, Metabolic Syndrome and Diabetes in Hispanics: implications on Cardiovascular Disease 2011 Eduardo de Marchena M.D., F.A.C.C., F.A.C.P. Professor.
Modern Management of Cholesterol in the High-Risk Patient.
Are you at Risk for a Stroke, Aneurysm or Peripheral Arterial Disease?
Peripheral Arterial Disease in Saudi Arabia : Where Do We Stand? Mohammed Al-Omran, MD, MSc, FRCSC Associate Professor & Vascular Surgeon, King Saud University.
Primordial, primary, secondary, and tertiary prevention stages for global vascular risk. R. Sacco: Stroke, Volume 38(6).June
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
C. Diehm, 2007 Excess cardiovascular mortality in patients with peripheral arterial disease in primary care: 5-year results of the getABI Study Diehm C,
Peripheral Arterial Disease - antiplatelet therapy Debora Karetová IInd Dept for Cardiology and Angiology General Faculty Hospital Ist Medical Faculty,
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
1 “Diabetic foot” Sensory Autonomic Motor. 2 Neuropathic: 45-60% Purely ischaemic: 10% Mixed neuroischaemic: 25-40% Diabetic foot ulceration.
ACC/AHA 2006 guidelines on the management of PAD.
ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations *Composite of CV death, nonfatal MI or stroke, revascularization,
Coronary Artery Calcium
Medical Management of Claudication: Just Walk it Off!!
2007 Hypertension as a Public Health Risk January, 2007.
Cardiovascular Disease (CVD) Objectives: Describe the movement of blood through the cardiovascular system Discuss the prevalence of CVD Define the types.
Incidence of Abnormal Ankle-Brachial Index in Diabetic Patients Asymptomatic of Arteriosclerotic Vascular disease Brintha Vasagar, MD, MPH, Katee Castleman,
Are We There Yet ? Abdul H. Sankari, MD FACC FCCP.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Peripheral Artery Disease (PAD)
Peripheral Interventions in the VA Healthcare System
CVD Part 2.
Copyright © 2009 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
FATS- Familial Atherosclerosis Treatment Study
Prashant Kaul, MD, FSCAI Piedmont Heart Institute, Atlanta, GA
L. Norgren, W. R. Hiatt, J. A. Dormandy, M. R. Nehler, K. A. Harris, F
Level of risk factor control in the overall sample and by gender
Cardiovascular Disease in Women Module III: Risk Assessment Tool
PROSPER: trial design                                                                                                                                                                 
Presentation transcript:

PAD A Call to Action

PAD: A Call to Action - What is peripheral arterial disease (PAD)? and why is it so dangerous? - Diagnosing PAD in the primary care setting - The importance of aggressive risk management of PAD - Evidence base for protecting patients with PAD

Major manifestations of atherothrombosis include Cerebrovascular disease Coronary artery disease Renal artery stenosis Visceral arterial disease Peripheral arterial disease –Intermittent claudication –Critical limb ischemia

Prevalence of metabolic syndrome in each patient group (%) Prevalence of metabolic syndrome in each patient group (%) Cross-Sectional survey of 1,045 vascular disease patients 40% CHD 43% 45% 57% Stroke AAA PAD Olijhoek JK et al. Eur Heart J 2004; 25: Metabolic syndrome is more common in PAD than in CHD or stroke AAA = Abdominal Aortic Aneurysm

Prevalence of PAD increases with age Figure adapted from Creager M, ed. Management of Peripheral Arterial Disease. Medical, Surgical and Interventional Aspects Meijer WT et al. Arterioscler Thromb Vasc Biol 1998; 18: Criqui MH et al. Circulation 1985; 71: Patients with PAD (%) Rotterdam Study (ABI Test <0.9) 1 San Diego Study (PAD by noninvasive tests) 2

Mortality is very high in patients with severe PAD Relative 5-year mortality 1. Criqui MH. Vasc Med 2001; 6 (suppl 1): 3–7. 2. McKenna M et al. Atherosclerosis 1991; 87: 119– Ries LAG et al. (eds). SEER Cancer Statistics Review, 1973–1997. US: National Cancer Institute; Patients (%) Colon/rectal cancer 1 Breast cancer 1 Severe PAD 2 Non-Hodgkin’s lymphoma

Resnick HE et al. Circulation 2004; 109: There is a strong two-way association between decreased ABI and increased risk for cardiovascular death 1 Baseline ABI* Percent <0.60 (n=25) <0.70 (n=21) 0.70-<0.80 (n=40) 0.80-<0.90 (n=130) 0.90-<1.0 (n=195) 1.0-<1.10 (n=980) All-cause mortality CVD Mortality *Mean participant follow-up 8.3 years

Guidance for PAD diagnosis STEP 1 Assess patient for risk factors Assess patient for risk factors – smoking – diabetes – hypertension – age: men >55 years and women >65 years – hyperlipidaemia – history of cardiovascular disease Assess patient for leg symptoms Assess patient for leg symptoms – intermittent claudication – critical limb ischaemia Tools: PAD checklist, Rose questionnaire, Tools: PAD checklist, Rose questionnaire, Edinburgh questionnaire Edinburgh questionnaire STEP 2 If suspicion of PAD, perform an ABI to confirm diagnosis using a hand-held Doppler If suspicion of PAD, perform an ABI to confirm diagnosis using a hand-held Doppler

Only 1 in 10 patients with PAD has classical symptoms of intermittent claudication Only 1 in 10 of these patients has classical symptoms of intermittent claudication (IC) 1 in 5 people over 65 has PAD † † ABI<0.9 Diehm C et al. Atherosclerosis 2004; 172;

A screening ABI should be performed in patients with diabetes The American Diabetes Association recommends screening for PAD in patients with diabetes 1. American Diabetes Association. Diabetes Care 2003; 26: Estes JM, Pomposelli FB Jr. Diabet Med 1996: 13: S43- S57. Those <50 years of age who have other risk factors associated with PAD Smoking Smoking Hypertension Hypertension Hyperlipidaemia Hyperlipidaemia Duration of diabetes Duration of diabetes >10 years >10 years Those >50 years of age If normal an exercise If normal an exercise test should be test should be carried out carried out The ABI test The ABI test should be repeated should be repeated every 5 years every 5 years Foot care is also important in diabetic patients as PAD is a major contributor to diabetic foot problems 2

Risk factor management approach Smoking cessation Smoking cessation Weight reduction Weight reduction Total cholesterol <175 mg/dL / <4.5 mmol/L Total cholesterol <175 mg/dL / <4.5 mmol/L LDL cholesterol <100 mg/dL / <2.6 mmol/L LDL cholesterol <100 mg/dL / <2.6 mmol/L Glycosylated haemoglobin <7.0% Glycosylated haemoglobin <7.0% Blood pressure (BP) <140/90 mm Hg Blood pressure (BP) <140/90 mm Hg – For patients with diabetes BP < 130/80mm Hg Platelet inhibition Platelet inhibition Hiatt WR. N Engl J Med 2001; 344:

Key learning points Ensure aggressive and early risk management of patients who are at high risk but may be asymptomatic Screen patients with diabetes >50 years of age, and those 50 years of age, and those <50 years of age who have additional risk factors associated with PAD Only 1 in 10 patients with PAD have typical claudication 1 Patients with diabetes are at high risk of PAD It is important to improve the management of PAD to protect patients from an increased risk of ischaemic events REMEMBERACTION 1. Diehm C et al. Atherosclerosis 2004; 172:

Overall learning points PAD is a reliable warning sign that a patient is at high risk for life threatening cardiovascular and cerebrovascular events PAD is easily overlooked by both patients and physicians – assess whether patients presenting with symptoms or associated risk factors have PAD Treatments are available to protect the patients with PAD from future MI or stroke

Help protect patients with PAD from their increased risk of MI or stroke